JP2019531344A - ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 - Google Patents

４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 Download PDF

Info

Publication number
JP2019531344A
JP2019531344A JP2019535993A JP2019535993A JP2019531344A JP 2019531344 A JP2019531344 A JP 2019531344A JP 2019535993 A JP2019535993 A JP 2019535993A JP 2019535993 A JP2019535993 A JP 2019535993A JP 2019531344 A JP2019531344 A JP 2019531344A
Authority
JP
Japan
Prior art keywords
composition
weight
crystals
liquid
oltipraz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019535993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531344A5 (https=
Inventor
クリス ガーランド アンソニー
クリス ガーランド アンソニー
アンネ ボルマン‐ケネディー バーバラ‐ジーン
アンネ ボルマン‐ケネディー バーバラ‐ジーン
フラムロゼ ボミ
フラムロゼ ボミ
ブレットバーナー
バーナー ブレット
エドワード グラス マイケル
エドワード グラス マイケル
キース ジャガー ケイシー
キース ジャガー ケイシー
ジェイ ブルーム コーリー
ジェイ ブルーム コーリー
ジョセフ カスタンティン マーク
ジョセフ カスタンティン マーク
Original Assignee
エスティー アイピー ホールディング エージー
エスティー アイピー ホールディング エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスティー アイピー ホールディング エージー, エスティー アイピー ホールディング エージー filed Critical エスティー アイピー ホールディング エージー
Priority claimed from PCT/IB2017/001312 external-priority patent/WO2018047013A1/en
Publication of JP2019531344A publication Critical patent/JP2019531344A/ja
Publication of JP2019531344A5 publication Critical patent/JP2019531344A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019535993A 2016-09-12 2017-09-12 ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 Pending JP2019531344A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201611031045 2016-09-12
IN201611031045 2016-09-12
US201662412681P 2016-10-25 2016-10-25
US62/412,681 2016-10-25
PCT/IB2017/001312 WO2018047013A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2019531344A true JP2019531344A (ja) 2019-10-31
JP2019531344A5 JP2019531344A5 (https=) 2020-11-05

Family

ID=60569947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535993A Pending JP2019531344A (ja) 2016-09-12 2017-09-12 ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法

Country Status (6)

Country Link
US (1) US11426403B2 (https=)
EP (1) EP3509642A1 (https=)
JP (1) JP2019531344A (https=)
KR (1) KR102658015B1 (https=)
CN (1) CN109996562A (https=)
AU (1) AU2017323504A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533008A (ja) * 2016-09-12 2019-11-14 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515453A (ja) * 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
JP2006511508A (ja) * 2002-11-26 2006-04-06 シージェー コーポレーション オルチプラズの製造方法
JP2007519714A (ja) * 2004-01-27 2007-07-19 シージェイ コーポレーション 低結晶性を有するか、または無定形化されたオルティプラッツの製造方法
JP2008521812A (ja) * 2004-11-24 2008-06-26 メドポイント ヘルスケア インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
JP2018520134A (ja) * 2015-06-25 2018-07-26 エステー イーペー ホールディング アーゲーＳＴ ＩＰ Ｈｏｌｄｉｎｇ ＡＧ オルチプラズを調製する方法
JP2019533008A (ja) * 2016-09-12 2019-11-14 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US7012148B2 (en) 2001-09-25 2006-03-14 Trustees Of Dartmouth College Compositions and methods for thionation during chemical synthesis reactions
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US20050182128A1 (en) 2002-02-13 2005-08-18 Stephen Lam Use of anethole dithiolethione in lung cancer chemoprevention
PL1696958T3 (pl) 2003-12-22 2007-08-31 Alcon Inc Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej
FR2879444B1 (fr) 2004-12-22 2007-05-18 Oreal Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
US20070036733A1 (en) 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
ES2668361T3 (es) 2005-08-15 2018-05-17 Givaudan Sa Compuestos refrigerantes
US7803353B2 (en) 2006-03-29 2010-09-28 The Procter & Gamble Company Oral care compositions having improved consumer aesthetics and taste
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
ATE540667T1 (de) 2007-06-13 2012-01-15 Givaudan Sa Verbindungen mit kühlender wirkung
US20110003747A1 (en) 2007-07-20 2011-01-06 Coloumbe Pierre A Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
EP2244699A2 (en) 2008-01-31 2010-11-03 Mcneil-PPC, Inc Edible film-strips for immediate release of active ingredients
EP2265126A4 (en) 2008-03-10 2011-06-29 Univ Louisville Res Found PROCESS AND COMPOSITIONS FOR THE CONTROLLED DELIVERY OF PHYTOCHEMICALS
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
EP2427170A2 (en) 2009-05-05 2012-03-14 Givaudan SA Organic compounds having cooling properties
CN102451469A (zh) * 2010-10-26 2012-05-16 沈阳药科大学 一类用于难溶性药物纳米系统的高效稳定剂
JP2014516080A (ja) 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
EP2757887B1 (en) 2011-09-22 2017-04-26 VIIV Healthcare UK Limited Pyrrolopyridinone compounds and methods for treating hiv
BR112015014523A2 (pt) * 2012-12-19 2017-07-11 Kashiv Pharma Llc nanossuspensão estabilizada, composição farmacêutica, e, método de tratamento de um paciente
US20160206641A1 (en) 2013-08-16 2016-07-21 Luminus Biosciences Inc. Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease
CN106029175A (zh) 2014-02-27 2016-10-12 宝洁公司 具有减少的苦味感受的口腔护理组合物
WO2016207914A2 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for preparing oltipraz
ITUB20159655A1 (it) 2015-12-23 2017-06-23 Bormioli Rocco Spa Capsula di sicurezza di un contenitore.
ITUA20162141A1 (it) 2016-03-31 2017-10-01 Bormioli Pharma Spa Capsula di chiusura
KR20180123796A (ko) 2017-05-10 2018-11-20 서울대학교산학협력단 Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515453A (ja) * 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
JP2006511508A (ja) * 2002-11-26 2006-04-06 シージェー コーポレーション オルチプラズの製造方法
JP2007519714A (ja) * 2004-01-27 2007-07-19 シージェイ コーポレーション 低結晶性を有するか、または無定形化されたオルティプラッツの製造方法
JP2008521812A (ja) * 2004-11-24 2008-06-26 メドポイント ヘルスケア インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
JP2018520134A (ja) * 2015-06-25 2018-07-26 エステー イーペー ホールディング アーゲーＳＴ ＩＰ Ｈｏｌｄｉｎｇ ＡＧ オルチプラズを調製する方法
JP2019533008A (ja) * 2016-09-12 2019-11-14 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMACOLOGYONLINE, vol. 2, JPN6021025232, 2010, pages 39 - 44, ISSN: 0004773501 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533008A (ja) * 2016-09-12 2019-11-14 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Also Published As

Publication number Publication date
AU2017323504A1 (en) 2019-05-02
CN109996562A (zh) 2019-07-09
US11426403B2 (en) 2022-08-30
AU2017323504A8 (en) 2019-06-06
KR102658015B1 (ko) 2024-05-21
US20190209556A1 (en) 2019-07-11
KR20190089852A (ko) 2019-07-31
EP3509642A1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
US20210052580A1 (en) Combination Compositions and Therapies Comprising 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, and Methods of Making and Using Same
EP2600838B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
Shaheen et al. Innovative coenzyme Q10-loaded nanoformulation as an adjunct approach for the management of moderate periodontitis: preparation, evaluation, and clinical study
WO2018047013A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
US20140147504A1 (en) Tetracycline topical formulations, preparation and uses thereof
JP7153429B2 (ja) 活性酸素消去剤
JP2023113634A (ja) ４－メチル－５－（ピラジン－２－イル）－３ｈ－１，２－ジチオール－３－チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法
WO2018047002A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
US11426403B2 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same
JP2017171643A (ja) 外用組成物
JP6735587B2 (ja) 外用組成物
US11135220B1 (en) Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
US20250057955A1 (en) Surfactants for use in healthcare products
KR20230145712A (ko) 히알루론산 코팅된 프러시안 블루 나노입자 및 용도
JP2021004267A (ja) 医薬組成物
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK1193764B (en) Liquid pharmaceutical composition comprising nitisinone
HK1193764A (en) Liquid pharmaceutical composition comprising nitisinone

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131